Informācijas avoti

 

Lapas sagatavošanā izmantotie informācijas avoti:

  • “Kas ir caureja?”, Latvijas Bērnu infektologu biedrība, Rīgas P.Stradiņa universitāte, Pediatrijas katedra
  • The National Institute of Diabetes and Digestive and Kidney Diseases (https://www.niddk.nih.gov)
  • National Institutes of Health (https://www.nih.gov)
  • UpToDate – uz pierādījumiem pamatota, publicētu informācijas kopsavilkumu datubāze mediķiem-profesionāļiem:
    • Acute diarrhea in adults, last updated 03.03.2008.
    • Acute diarrhea in children, last updated 12.03.2008.
    • Chronic diarrhea in adults, last updated 26.03.2007.
    • Antibiotic-associated diarrhea, last updates 11.02.2008.
  • Dale J J Pediatr Health Care 2004 Jul–Aug; Vol. 18 (4), pp. 211–2
  • Villarruel G. et al Acta Pediatr.2007; 96 : 538–541
  • Doron SI et al. J Clin Gastroenterol. 2008 Jul; 42 Suppl 2 : S 58–6
  • D’Souza et al. Br Med J 2002; 324 : 1361–7
  • Billoo, et al. World Journal of Gastroenterology. 2006; 12 (28) : 4557–4560
  • Szajewska, et al. Aliment Pharmacol Ther, 2007, 25 (3), 257–264
  • Szajewska, Aliment Pharmacol Ther 2005; 22 : 365–372
  • Kollaritsch H, et al. Travel Medicine International. 1989 : 9–17
  • Swidsinski A et al. Gastroenterology. 2008; 135 (2) : 568–579
  • Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Gastroenterol, 2011; 45: 679 – 83.
  • Shan & al. Beneficial microbes. In press 2013.
  • Saccharomyces boulardii interferes with Enterohemorrhagic Escherichia coli – induced signalling pathways in T84 cells. Dahan et al., Infection and immunity, 2003; 71(2): 766 – 773.
  • Czerucka D. Alimentary Pharmacology&Therapeutics. 2007; 26: 767 – 778.
  • Szajewska H, Skorka A. Meta-Analysis: Saccharomyces boulardii for treating acute diarrhoea in children, Aliment Pharmacol Ther, 2009.